• Our focus:

    Ub Ligases are proven to be critically
    involved in disease pathogenesis for oncology,
    inflammation and infectious disease

    Learn more
  • Our focus:

    Innovative screening method
    is a simple, one-step assay
    for inhibitors and activators.

    Learn more
  • Our focus:

    1st in class drugs specifically
    targeted at Ubiquitin (Ub) ligases

    Learn more
Funding from Breakout Labs just Announced

home-1

E3x Bio is the first company with exclusive focus on the development of inhibitors and activators of E3 Ubiquitin (Ub) ligases for drug discovery and development. This class of medically important enzymes is considered an important target for diseases ranging from cancer to neurodegeneration, but has been inaccessible to high-throughput drug screening because the current assays are cumbersome, indirect, and rely on a complex reaction mixture than can be complicated by multiple protein activities. E3X Bio’s streamlined screening paradigm and direct cellular and animal model assays, allow a simplified and pragmatic drug discovery approach to identify first-in-class small molecules specifically directed towards Ub E3 HECT ligases.

 

who we are

About E3X Bio

E3x Bio is the first company with exclusive focus on inhibitors and activators of E3 Ubiquitin (Ub) ligases for drug discovery and development. This class of medically relevant enzymes is considered an important target for diseases ranging from cancer to neurodegeneration, but has been inaccessible to high-throughput drug screening because the current assays are cumbersome, indirect, and rely on a complex reaction mixture than can be complicated by multiple protein activities. E3X Bio’s streamlined screening paradigm and direct cellular and animal model assays, allow a simplified, pragmatic drug discovery approach to identify first-in-class small molecules specifically directed towards Ub E3 HECT ligases.

The team

The founding scientific team has substantial prior drug development experience, including novel assets that are currently in human clinical studies: CEO Lori Rafield, Ph.D., at Apax Partners; Paul Godowski, Ph.D., at Genentech; Dave Morgans, Ph.D., at Roche/Syntex and Cytokinetics; and, Bill Harte, Ph.D., at BMS and Amgen.

our partners